Published date: Jun 10 2023

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 21, Issue No. 5

Pages: 367–378

DOI: 10.18502/ijrm.v21i5.13470

Seyed Sobhan Bahreinybahreiny.s@ajums.ac.irStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Elnaz HarooniStudent Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Mohammad Reza DabbaghDepartment of Biology, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran.

Reza EbrahimiDepartment of Cell and Molecular Biology, Faculty of Chemistry, University of Kashan, Kashan, Iran.

Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with complex pathogenesis and metabolic complications, such as insulin resistance. Among the new markers, preptin seems to play a significant role in metabolic disorders.

Objective: This meta-analysis was conducted to determine the relationship between circulating preptin levels and PCOS.

Materials and Methods: A systematic review and meta-analysis was performed to identify relevant articles in electronic databases such as PubMed, Web of Science, Scopus, Cochrane, EMBASE, and the Google Scholar search engine, using a predefined search strategy. A random-effects model was used to combine standard mean difference (SMD) and 95% CI to compare results between groups. Metaregression and subgroup analysis were also performed to reveal the sources of heterogeneity.

Results: The meta-analysis encompassed a total of 8 studies and 582 participants. The results indicate a statistically significant association between PCOS and serum preptin levels, with a pooled standardized mean difference (SMD = 1.35; 95% CI: 0.63- 2.08; p < 0.001). Further analysis suggested a significant difference in serum preptin levels between women with PCOS and higher homeostatic model assessment for insulin resistance ratio (SMD = 2.40; 95% [CI]: 1.17-3.63; p < 0.001) within the subgroup.

Conclusion: Our meta-analysis shows that increased serum preptin levels are associated with PCOS, suggesting that preptin may be related to the pathogenesis of PCOS and may be recognized as a novel diagnostic biomarker for PCOS. However, further studies are needed to confirm our results.

Key words: Polycystic ovary syndrome, Proinsulin-like growth factor II, Preptin, Meta-analysis.

[1] Zeng X, Xie Y-J, Liu Y-T, Long S-L, Mo Z-C. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta 2020; 502: 214–221.

[2] Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012; 97: 28– 38.e25.

[3] Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015; 36: 487–525.

[4] Banting LK, Gibson-Helm M, Polman R, Teede HJ, Stepto NK. Physical activity and mental health in women with polycystic ovary syndrome. BMC Womens Health 2014; 14: 51.

[5] Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: A systematic review and meta-analysis. Endocrine 2018; 62: 318–325.

[6] Witchel SF, Teede HJ, Pena AS. Curtailing PCOS. Pediatr Res 2020; 87: 353–361.

[7] Aversa A, La Vignera S, Rago R, Gambineri A, Nappi RE, Calogero AE, et al. Fundamental concepts and novel aspects of polycystic ovarian syndrome: Expert consensus resolutions. Front Endocrinol 2020; 11: 516.

[8] Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270–284.

[9] Bachelot A. Polycystic ovarian syndrome: Clinical and biological diagnosis. Ann Biol Clin 2016; 74: 661–667.

[10] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19–25.

[11] Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565–4592.

[12] Baldani DP, Skrgatic L, Ougouag R. Polycystic ovary syndrome: Important underrecognised cardiometabolic risk factor in reproductive-age women. Int J Endocrinol 2015; 2015: 786362.

[13] Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): An update. Arch Gynecol Obstet 2021; 303: 631–643.

[14] Bannigida DM, Nayak BS, Vijayaraghavan R. Insulin resistance and oxidative marker in women with PCOS. Arch Physiol Biochem 2020; 126: 183–186.

[15] Deveer R, Engin-Ustun Y, Uysal S, Su FA, Sarıaslan S, Gülerman C, et al. Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 602– 605.

[16] Kruszewska J, Laudy-Wiaderny H, Kunicki M. Review of novel potential insulin resistance biomarkers in PCOS patients-the debate is still open. Int J Environ Res Public Health 2022; 19: 2099.

[17] Celik O, Celik N, Hascalik S, Sahin I, Aydin S, Ozerol E. An appraisal of serum preptin levels in PCOS. Fertil Steril 2011; 95: 314–316.

[18] Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 2001; 360: 431–439.

[19] van Doorn J. Insulin-like growth factor-II and bioactive proteins containing a part of the E-domain of proinsulin- like growth factor-II. Biofactors 2020; 46: 563– 578.

[20] Aydin S. Three new players in energy regulation: Preptin, adropin and irisin. Peptides 2014; 56: 94–110.

[21] Yang G, Li L, Chen W, Liu H, Boden G, Li K. Circulating preptin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Ann Med 2009; 41: 52– 56.

[22] Ali HA, Abbas HJ, Naser AN. Preptin and adropin levels as new predictor in women with polycystic ovary syndrome. J Pharm Sci Res 2018; 10: 3005–3008.

[23] Mierzwicka A, Bolanowski M. New peptides players in metabolic disorders. Postepy Hig Med Dosw 2016; 70: 881–886.

[24] Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med 2017; 26: 359–367.

[25] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Esp Cardiol 2021; 74: 790–799.

[26] Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg 2011; 39: 91–92.

[27] Mehmet Ak, Bertan Demir M. An assesment of relationship between serum preptin levels and antimullerian hormone in infertile womens with polycystic ovary syndrome. Ann Clin Anal Med 2022; 13: 779–782.

[28] Ascar IF, Hameed AS. Serum prolactin, Preptin, CCL 18 and genetic polymorphisms in Iraqi women with polycystic ovary syndrome. Baghdad Sci J 2021; 18: 1552–1556.

[29] Senturk S, Hatirnaz S, Kanat-Pektas M. Serum preptin and amylin levels with respect to body mass index in polycystic ovary syndrome patients. Med Sci Monit 2018; 24: 7517–7523.

[30] Celik N, Aydin S, Ugur K, Yardim M, Acet M, Yavuzkir S, et al. Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS. Cell Mol Biol 2018; 64: 7–12.

[31] Mierzwicka A, Kuliczkowska-Plaksej J, Kolackov K, Bolanowski M. Preptin in women with polycystic ovary syndrome. Gynecol Endocrinol 2018; 34: 470–475.

[32] Bu Z, Kuok K, Meng J, Wang R, Xu B, Zhang H. The relationship between polycystic ovary syndrome, glucose tolerance status and serum preptin level. Reprod Biol Endocrinol 2012; 10: 10.

[33] Stang A. Critical evaluation of the Newcastle- Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.

[34] Andrade C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: As simple as it gets. J Clin Psychiatry 2020; 81: 20f13681.

[35] Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2016; 27: 1785–1805.

[36] Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–1558.

[37] Ades AE, Lu G, Higgins JPT. The interpretation of random-effects meta-analysis in decision models. Med Decis Making 2005; 25: 646–654.

[38] Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.

[39] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.

[40] Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. 2nd Ed. UK: John Wiley & Sons; 2019.

[41] Patel S. Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy. J Steroid Biochem Mol Biol 2018; 182: 27–36.

[42] Xiao C, Li W, Lu T, Wang J, Han J. Preptin promotes proliferation and osteogenesis of MC3T3-E1 cells by upregulating β-catenin expression. IUBMB Life 2019; 71: 854–862.

[43] Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest 2017; 40: 1–8.